生命科学资讯

Chutes & Ladders—Metabolic marketing master maneuvers to CEO

Cycle seizes struggling Applied Tx, picking up rare disease biotech for pennies per share

Arcus discontinues Gilead-partnered TIGIT trials due to futility

2026 outlook: Biotech poised to outperform bear markets of ’21-24, analyst says

Leading the Way in Biotech Solutions Across Japan and Asia Pacific (JAPAC)

Amgen obesity marketing leader Chris Boulton takes reins at metabolic biotech Prolynx

HeartBeam swells on turning FDA rejection into ECG clearance

Lilly's obesity triple threat smashes efficacy expectations in phase 3 but proves intolerable for some

Rezolute's stock plunges 87% after hypoglycemia drug flunks pivotal phase 3 test

FDA clears Lumosity brain training games as a prescription app for adult ADHD

GRI touts IPF safety edge, lung function gains amid cash crunch

Zealand pens $2.5B oral cardiometabolic collab with fresh-faced Chinese biotech

FDA approves 1st nondrug, at-home treatment for depression

Apple Tree Partners files for bankruptcy to keep cash flowing to portfolio biotechs

Francis Medical gets FDA green light for water vapor ablation to treat prostate cancer

Bleecker's big bang: Formation Bio unveils new subsidiary with $605M Lynk deal

Sanofi, GSK ink preclinical pacts in quest for new autoimmune and cancer antibodies

Chinese biotech led by AstraZeneca veteran reels in $108M for KRAS phase 3 plans

Roche links oral SERD to 30% breast cancer risk reduction in phase 3 adjuvant trial

Rainbows, pickleball and puppies: Inside the ‘enduring activism’ and ‘cautious optimism’ at ASH 2025